AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24160483 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity reminders provided by a health care aide peer
Number of subjects: 24
Study 21285288 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic ankle-foot orthosis
Number of subjects: 28
Study 21285288 — intervention group
Group type: COMPARATOR
Intervention: Tennis shoes (Control)
Number of subjects: 28
Study 19596505 — intervention group
Group type: EXPERIMENTAL
Intervention: Trident Xtra Care
Number of subjects: 10
Study 19596505 — intervention group
Group type: EXPERIMENTAL
Intervention: Orbit Professional
Number of subjects: 10
Study 19596505 — intervention group
Group type: EXPERIMENTAL
Intervention: Orbit
Number of subjects: 10
Study 19596505 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra
Number of subjects: 10
Study 27770145 — intervention group
Group type: EXPERIMENTAL
Intervention: 186Re-HEDP administered at levels above 3.5 GBq
Number of subjects: 57
Study 27770145 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient mean absorbed dose
Number of subjects: 57
Study 27770145 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body absorbed dose
Number of subjects: 57
Study 27770145 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease volume as measured from SPECT imaging
Number of subjects: 57
Study 27770145 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease volume in multivariable analysis
Number of subjects: 57
Study 16287345 — intervention group
Group type: EXPERIMENTAL
Intervention: Training group (n = 36)
Number of subjects: 45
Study 16287345 — intervention group
Group type: COMPARATOR
Intervention: Nonexercise control group (n = 9)
Number of subjects: 45
Study 12161476 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily hGH therapy (6 mg/m2 weekly)
Number of subjects: 38
Study 12161476 — intervention group
Group type: COMPARATOR
Intervention: Alternate day hGH therapy (6 mg/m2 weekly)
Number of subjects: 38
Study 12161476 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative growth velocity over 4 years (2 years on and 2 years off therapy)
Number of subjects: 38
Study 12161476 — intervention group
Group type: EXPERIMENTAL
Intervention: Adult height prediction after 4 years
Number of subjects: 38
Study 10532694 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin infusion
Number of subjects: 8
Study 10532694 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 8
Study 7762500 — intervention group
Group type: EXPERIMENTAL
Intervention: Monophasic waveform (Edmark)
Number of subjects: 171
Study 7762500 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic waveform (Gurvich)
Number of subjects: 171
Study 7762500 — intervention group
Group type: EXPERIMENTAL
Intervention: Monophasic waveform (Edmark) for VF
Number of subjects: 171
Study 7762500 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic waveform (Gurvich) for VF
Number of subjects: 171
Study 2140030 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture at the P6 point for 15 minutes
Number of subjects: 100
Study 2140030 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation at the P6 point for 15 minutes
Number of subjects: 100
Study 2140030 — intervention group
Group type: EXPERIMENTAL
Intervention: Prochlorperazine 5 mg intravenously
Number of subjects: 100
Study 2140030 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control group)
Number of subjects: 100
Study 343862 — intervention group
Group type: EXPERIMENTAL
Intervention: 75Se‐labelled amino acids
Number of subjects: 22
Study 343862 — intervention group
Group type: EXPERIMENTAL
Intervention: Two of the 75Se‐labelled amino acids
Number of subjects: 22
Study 30664895 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy with 6 months of androgen deprivation therapy
Number of subjects: 204
Study 30664895 — intervention group
Group type: COMPARATOR
Intervention: Radiation therapy without androgen deprivation therapy
Number of subjects: 204
Study 28612123 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (1000 mg)
Number of subjects: 15
Study 28612123 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 27108466 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 1.5 mg/kg
Number of subjects: 50
Study 27108466 — intervention group
Group type: COMPARATOR
Intervention: Rocuronium 0.6 mg/kg
Number of subjects: 50
Study 23402500 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary infiltration of 1 cartridge of 4% articaine with 1:100,000 epinephrine
Number of subjects: 100
Study 23402500 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat infiltration of 1 cartridge of 4% articaine with 1:100,000 epinephrine after 20 minutes
Number of subjects: 100
Study 23402500 — intervention group
Group type: COMPARATOR
Intervention: Mock repeat infiltration
Number of subjects: 100
Study 22403979 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.454% stannous fluoride (SnF2) dentifrice
Number of subjects: 28
Study 22403979 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine digluconate (AlF3/Chx) dentifrice
Number of subjects: 28
Study 19486077 — intervention group
Group type: EXPERIMENTAL
Intervention: Zirconia abutments
Number of subjects: 22
Study 19486077 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium abutments
Number of subjects: 22
Study 16289980 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone propionate (FP) 1000 microg bid
Number of subjects: 37
Study 16289980 — intervention group
Group type: COMPARATOR
Intervention: Oral prednisone (P)
Number of subjects: 37
Study 16289980 — intervention group
Group type: COMPARATOR
Intervention: Both FP and P
Number of subjects: 37
Study 14695986 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture and moxa treatment at therapeutic points
Number of subjects: 19
Study 14695986 — intervention group
Group type: COMPARATOR
Intervention: Indifferent points (Control Group)
Number of subjects: 19
Study 10870872 — intervention group
Group type: EXPERIMENTAL
Intervention: Zaleplon 5 mg
Number of subjects: 0
Study 10870872 — intervention group
Group type: EXPERIMENTAL
Intervention: Zaleplon 10 mg
Number of subjects: 0
Study 10870872 — intervention group
Group type: EXPERIMENTAL
Intervention: Zaleplon 20 mg
Number of subjects: 0
Study 10870872 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg
Number of subjects: 0
Study 10870872 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8818850 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (500 mg once daily for 3 days)
Number of subjects: 67
Study 8818850 — intervention group
Group type: COMPARATOR
Intervention: Co-amoxiclav (625 mg three times daily for 10 days)
Number of subjects: 67
Study 8818850 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 67
Study 8818850 — intervention group
Group type: COMPARATOR
Intervention: Co-amoxiclav
Number of subjects: 67
Study 1430361 — intervention group
Group type: EXPERIMENTAL
Intervention: 15% paromomycin sulfate and 12% methylbenzethonium chloride (15/12 P-ointment)
Number of subjects: 39
Study 1430361 — intervention group
Group type: EXPERIMENTAL
Intervention: 15% paromomycin sulfate and 5% methylbenzethonium chloride (15/5 P-ointment)
Number of subjects: 39
Study 1430361 — intervention group
Group type: COMPARATOR
Intervention: Placebo ointment
Number of subjects: 39
Study 6100870 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (10-40 mg q.d.)
Number of subjects: 53
Study 6100870 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (10-40 mg q.d.) + Hydrochlorothiazide (50 mg/day)
Number of subjects: 53
Study 6100870 — intervention group
Group type: COMPARATOR
Intervention: Enalapril (40 mg) + Hydrochlorothiazide (50, 25, 12.5 mg/day)
Number of subjects: 53
Study 6100870 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril alone
Number of subjects: 53
Study 6100870 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 53
Study 6100870 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril + Hydrochlorothiazide
Number of subjects: 53
Study 31066883 — intervention group
Group type: EXPERIMENTAL
Intervention: PUVA induction regimen (12- to 24-week duration)
Number of subjects: 27
Study 28766879 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin (bolus 0.75 mg/kg followed by infusion of 1.75 mg/kg, extra bolus 0.3 mg/kg before stenting)
Number of subjects: 84
Study 28766879 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH, 100 IU/kg)
Number of subjects: 84
Study 28766879 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 84
Study 28766879 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH)
Number of subjects: 84
Study 28766879 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin and UFH
Number of subjects: 84
Study 26382728 — intervention group
Group type: EXPERIMENTAL
Intervention: 560 mg oral ibrutinib, fasting conditions
Number of subjects: 0
Study 26382728 — intervention group
Group type: EXPERIMENTAL
Intervention: 560 mg oral ibrutinib, fed, after glucose drink
Number of subjects: 0
Study 26382728 — intervention group
Group type: EXPERIMENTAL
Intervention: 140 mg oral ibrutinib, fed, with grapefruit juice before dosing
Number of subjects: 0
Study 24569887 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV testing routines
Number of subjects: 580
Study 24569887 — intervention group
Group type: EXPERIMENTAL
Intervention: STI testing routines
Number of subjects: 580
Study 24569887 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge, beliefs, attitudes, subjective norms, perceived behavioral control
Number of subjects: 580
Study 22572105 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation
Number of subjects: 420
Study 22572105 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 420
Study 22572105 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast milk DHA
Number of subjects: 420
Study 20190538 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRHa combined with GH
Number of subjects: 46
Study 20190538 — intervention group
Group type: COMPARATOR
Intervention: GnRHa
Number of subjects: 46
Study 20190538 — intervention group
Group type: EXPERIMENTAL
Intervention: TW3 method
Number of subjects: 46
Study 20190538 — intervention group
Group type: EXPERIMENTAL
Intervention: GP method
Number of subjects: 46
Study 20190538 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment
Number of subjects: 46
Study 18301927 — intervention group
Group type: EXPERIMENTAL
Intervention: Interbody fusion cage containing beta‐TCP with supplemented anterior plate (n = 33)
Number of subjects: 62
Study 18301927 — intervention group
Group type: COMPARATOR
Intervention: Interbody fusion cage containing beta‐TCP without supplemented anterior plate (n = 29)
Number of subjects: 62
Study 18301927 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (with and without plate fixation)
Number of subjects: 62
Study 16507379 — intervention group
Group type: EXPERIMENTAL
Intervention: Switching from olanzapine to risperidone
Number of subjects: 121
Study 12005275 — intervention group
Group type: EXPERIMENTAL
Intervention: Rizatriptan 5 mg
Number of subjects: 296
Study 12005275 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 296
Study 10220208 — intervention group
Group type: EXPERIMENTAL
Intervention: NN304 (0.15 U/kg)
Number of subjects: 11
Study 10220208 — intervention group
Group type: EXPERIMENTAL
Intervention: NN304 (0.3 U/kg)
Number of subjects: 11
Study 10220208 — intervention group
Group type: EXPERIMENTAL
Intervention: NN304 (0.6 U/kg)
Number of subjects: 11
Study 10220208 — intervention group
Group type: COMPARATOR
Intervention: NPH-insulin (0.3 U/kg)
Number of subjects: 11
Study 8697123 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyurethane foam hydrophilic dressing (Allevyn)
Number of subjects: 0
Study 8697123 — intervention group
Group type: COMPARATOR
Intervention: Calcium sodium alginate dressing (Kaltostat)
Number of subjects: 0
Study 1662885 — intervention group
Group type: EXPERIMENTAL
Intervention: Temafloxacin 200 mg
Number of subjects: 421
Study 1662885 — intervention group
Group type: EXPERIMENTAL
Intervention: Temafloxacin 400 mg
Number of subjects: 421
Study 1662885 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone 250 mg
Number of subjects: 421
Study 7045975 — intervention group
Group type: EXPERIMENTAL
Intervention: Telepaque (iopanoic acid) given with food (TF)
Number of subjects: 15
Study 7045975 — intervention group
Group type: EXPERIMENTAL
Intervention: Telepaque (iopanoic acid) given without food (T)
Number of subjects: 15
Study 7045975 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilopaque (sodium tyropanoate) given without food
Number of subjects: 15
Study 7045975 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Telepaque and Bilopaque (TF-B)
Number of subjects: 15
Study 7045975 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Telepaque given with food (TF) and Telepaque given without food (TF-TF)
Number of subjects: 15
Study 7045975 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Telepaque given without food (T) and Telepaque given without food (T-T)
Number of subjects: 15
Study 31368269 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture plus medication (Tamsulosin 0.2 mg/d for 8 weeks)
Number of subjects: 60
Study 31368269 — intervention group
Group type: COMPARATOR
Intervention: Medication (Tamsulosin 0.2 mg/d for 8 weeks)
Number of subjects: 60
Study 31368269 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture plus medication
Number of subjects: 60
Study 29935972 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct Anterior Approach (DAA)
Number of subjects: 30
Study 29935972 — intervention group
Group type: COMPARATOR
Intervention: Anterolateral Approach (ALA)
Number of subjects: 30
Study 25963332 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesiology Taping (KT) with pneumatic and manual lymphatic drainage
Number of subjects: 70
Study 25963332 — intervention group
Group type: EXPERIMENTAL
Intervention: Quasi-Kinesiology Taping with pneumatic and manual lymphatic drainage
Number of subjects: 70
Study 25963332 — intervention group
Group type: COMPARATOR
Intervention: Standard procedure - pneumatic and manual lymphatic drainage and multilayered bandaging
Number of subjects: 70
Study 25182250 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 212
Study 25182250 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 212
Study 21943828 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative education (usual care plus an information leaflet and verbal advice)
Number of subjects: 153
Study 21943828 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 153
Study 20139678 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA supplementation in infant formula for preterm infants
Number of subjects: 0
Study 20139678 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA supplementation during pregnancy and/or lactation
Number of subjects: 0
Study 20139678 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA supplementation timing and dose
Number of subjects: 0
Study 18341564 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 20% patch (DentiPatch)
Number of subjects: 31
Study 18341564 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine 5% gel
Number of subjects: 31
Study 16522892 — intervention group
Group type: EXPERIMENTAL
Intervention: PTFI (Pharmacist Telephone Follow-up Intervention)
Number of subjects: 255
Study 16522892 — intervention group
Group type: COMPARATOR
Intervention: UPI (Usual Pharmacist Intervention)
Number of subjects: 255
Study 12386637 — intervention group
Group type: COMPARATOR
Intervention: Fixed 800 mg/d ribavirin
Number of subjects: 0
Study 12386637 — intervention group
Group type: EXPERIMENTAL
Intervention: Body weight-based 800/1000/1200 mg/d ribavirin
Number of subjects: 0
Study 12386637 — intervention group
Group type: EXPERIMENTAL
Intervention: 13 mg/kg per day ribavirin
Number of subjects: 0
Study 10442910 — intervention group
Group type: EXPERIMENTAL
Intervention: Cataract surgery
Number of subjects: 5342
Study 10442910 — intervention group
Group type: COMPARATOR
Intervention: Control group (no surgery)
Number of subjects: 5342
Study 7561805 — intervention group
Group type: EXPERIMENTAL
Intervention: PM vaccine (Pasteur Mérieux)
Number of subjects: 839
Study 7561805 — intervention group
Group type: COMPARATOR
Intervention: SKB vaccine (Smith‐Kline Beecham)
Number of subjects: 839
Study 2140854 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (8 mg loading dose: 4 mg IV plus 4 mg orally, followed by 8 mg every 8 hours orally for 3 to 5 days)
Number of subjects: 75
Study 2140854 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide (80 mg loading dose: 60 mg IV plus 20 mg orally, followed by 20 mg every 8 hours orally for 3 to 5 days)
Number of subjects: 75
Study 2140854 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 75
Study 2140854 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide
Number of subjects: 75
Study 443500 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician prescribed exercise with health education
Number of subjects: 124
Study 443500 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring
Number of subjects: 124
Study 443500 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 124
Study 30569245 — intervention group
Group type: EXPERIMENTAL
Intervention: AB928 (10 to 200 mg once daily and 100 mg twice daily)
Number of subjects: 85
Study 30569245 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study 29275794 — intervention group
Group type: EXPERIMENTAL
Intervention: Real acupuncture
Number of subjects: 22
Study 29275794 — intervention group
Group type: EXPERIMENTAL
Intervention: Sham acupuncture
Number of subjects: 22
Study 23835673 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol (0.5 mg/kg)
Number of subjects: 60
Study 23835673 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil (1 μg/kg)
Number of subjects: 60
Study 23507173 — intervention group
Group type: COMPARATOR
Intervention: 0 g GOS (Control)
Number of subjects: 31
Study 23507173 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 g GOS
Number of subjects: 31
Study 23507173 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g GOS
Number of subjects: 31
Study 21205361 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural body image therapy (10 group sessions)
Number of subjects: 32
Study 21205361 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control condition
Number of subjects: 32
Study 19667282 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month therapy
Number of subjects: 90
Study 19667282 — intervention group
Group type: COMPARATOR
Intervention: 9-month therapy
Number of subjects: 90
Study 17464696 — intervention group
Group type: EXPERIMENTAL
Intervention: Five SNPs (rs2494732, rs2498799, rs3730358, rs1130214, rs3803300)
Number of subjects: 641
Study 17464696 — intervention group
Group type: EXPERIMENTAL
Intervention: Five-SNP haplotypes
Number of subjects: 641
Study 17464696 — intervention group
Group type: EXPERIMENTAL
Intervention: Five domain scores (processing speed, reasoning, verbal memory, working memory, vigilance)
Number of subjects: 641
Study 15276392 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (75 mg/day) + Clopidogrel (75 mg/day)
Number of subjects: 7599
Study 15276392 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel (75 mg/day) alone
Number of subjects: 7599
Study 11689577 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine 1,250 mg/m² administered twice daily days 1 to 14 every 3 weeks
Number of subjects: 602
Study 11689577 — intervention group
Group type: COMPARATOR
Intervention: Intravenous 5-FU plus leucovorin (5-FU/LV)
Number of subjects: 602
Study 10774973 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomly alternating imaging conditions (y-axis inverted and normal laparoscopic)
Number of subjects: 32
Study 10774973 — intervention group
Group type: COMPARATOR
Intervention: Full binocular imaging
Number of subjects: 32
Study 10774973 — intervention group
Group type: COMPARATOR
Intervention: Y-axis inverted imaging
Number of subjects: 32
Study 10774973 — intervention group
Group type: COMPARATOR
Intervention: Normal laparoscopic imaging
Number of subjects: 32
Study 8944406 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking
Number of subjects: 0
Study 1280737 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 57
Study 1280737 — intervention group
Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 57
Study 6424854 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 39
Study 6424854 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 31078146 — intervention group
Group type: EXPERIMENTAL
Intervention: M1E1, M1E5, M5E3, M5E4, M5E5 primer combinations
Number of subjects: 13
Study 31078146 — intervention group
Group type: EXPERIMENTAL
Intervention: M5E1 primer pair
Number of subjects: 13
Study 31078146 — intervention group
Group type: EXPERIMENTAL
Intervention: M4E4 primer combination
Number of subjects: 13
Study 31078146 — intervention group
Group type: EXPERIMENTAL
Intervention: M2E3 primer combination
Number of subjects: 13
Study 31078146 — intervention group
Group type: EXPERIMENTAL
Intervention: M4E3 primer combination
Number of subjects: 13
Study 31078146 — intervention group
Group type: EXPERIMENTAL
Intervention: M2E5, M4E1, M5E1 primer combinations
Number of subjects: 13
Study 31078146 — intervention group
Group type: EXPERIMENTAL
Intervention: M3E1 primer combination
Number of subjects: 13
Study 31078146 — intervention group
Group type: EXPERIMENTAL
Intervention: M2E1, M2E2, M4E1, M5E3 primer combinations
Number of subjects: 13
Study 31078146 — intervention group
Group type: EXPERIMENTAL
Intervention: M2E4 primer combination
Number of subjects: 13
Study 31078146 — intervention group
Group type: EXPERIMENTAL
Intervention: M1E5, M2E2, M3E2 primer combinations
Number of subjects: 13
Study 31078146 — intervention group
Group type: EXPERIMENTAL
Intervention: M1E2, M2E3, M5E5 primer combinations
Number of subjects: 13
Study 29873529 — intervention group
Group type: EXPERIMENTAL
Intervention: HTX-019 130 mg (30-min infusion)
Number of subjects: 200
Study 29873529 — intervention group
Group type: COMPARATOR
Intervention: fosaprepitant 150 mg (20- or 30-min infusion)
Number of subjects: 200
Study 26395352 — intervention group
Group type: EXPERIMENTAL
Intervention: 38% Silver diamine fluoride (SDF)
Number of subjects: 16